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Donor livers are a scarce, life-saving resource. For patients whose
lives depend upon liver transplantation, the policies deﬁning pri-
ority for donor livers are of ultimate importance. Fair and just uti-
lization of available livers requires that policy makers understand
how to balance the needs and interests of each of the stakehold-
ers. Although signiﬁcant medical and surgical advances have
been made in the last three decades, many patients who undergo
liver transplantation will eventually have early complications or
recurrent liver disease resulting in failure of their transplanted
liver graft. When this occurs, repeat liver transplantation is often
the only deﬁnitive treatment. Unfortunately, retransplantation
has lower graft survival rates than primary transplant (Fig. 1).
Numerous prognostic models have been developed to aid clinical
decision-making as to whether or not pursuit of retransplanta-
tion can be justiﬁed based on the estimated survival after
retransplantation. The fundamental principles of medical ethics
i.e. autonomy, non-malfeasance, beneﬁcence, justice, and utility
can further inform the rational application of prognostic models
to retransplantation. Yet, to do so, will require a blunt and frank
dialogue, within our transplant community and society at large,
about the concepts of futility and rationing.
Medical and surgical advancements of the last 3 decades have
established liver transplantation as a lifesaving intervention for
patients with advanced liver disease that is now available in most
regions of the world. In general, long term patient survival after
liver transplantation is excellent, particularly when compared
to the survival of patients with end stage liver disease without
transplantation. For example, in the United States, patient sur-
vival after liver transplantation is 88%, 74%, and 60% at 1, 5,
and 10 years nationally, with single center reports of long term
patient survival as high as 68% and 64% at 10 and 15 years,
respectively [1,2]. The ubiquitous application of the procedureJournal of Hepatology 20
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retransplant; UK, United Kingdom; US, United States.is limited by the scarcity of available liver grafts. Despite efforts
to expand the donor pool and improve systems to triage liver
grafts, death rates while waiting for liver transplantation remain
high [1]. Liver transplant candidates on the waiting list in the US
with a MELD score of 15 and 40 have a mortality rate of 146 and
13,152 per 1000 patient-years, respectively, whereas the 1-year
post-transplant mortality rate is 183 [3]. By comparison, patients
undergoing repeat liver transplantation, have a 1-year mortality
rate in the US of 264 deaths per 1000 patient-years [4]. Therefore,
once decompensated liver disease occurs in the native liver or a
liver graft, from individual patient perspective, there is generally
a net survival beneﬁt with liver transplantation if a liver graft is
available. Unfortunately, the gap between the supply of liver
grafts and the demand for liver transplantation remains wide
and without prospects to narrow in the foreseeable future.
The global success of liver transplantation has extended lives
of many patients worldwide with an estimated 149,470 liver
transplants performed in just the 10-year period from 2000 to
2009 [5]. In the US, the Scientiﬁc Registry of Transplant Recipi-
ents estimated that as a result of the 88,160 liver transplants that
were performed from 1988 to 2007, there were over 42,286 peo-
ple living with a functioning liver graft in 2008 [6]. Although esti-
mates of the number of people living with a functional liver graft
worldwide remains poorly quantiﬁed, assuming a 5-year survival
rate of 40–70% with an exponential survival distribution and an
annual number of liver transplants of about 15,000 over the last
10 years, one can estimate that from the last decade alone, there
would be 77,648–118,461 people worldwide living with a func-
tioning liver graft in 2011. This large population of persons living
with a functioning liver graft after a ﬁrst transplant represents a
growing pool of individuals who are at risk for graft failure, many
of whom may eventually seek a second liver transplant (Fig. 2).
Additionally, liver graft scarcity has motivated the transplant
community to expand the donor pool by using liver grafts with
a higher donor risk index (DRI) that are at greater risk of early
graft failure from primary non-function (PNF), hepatic artery
thrombosis (HAT) or ischemic type biliary injury. In the US during
the period from 1999 to 2008, there was a 38% increase in the use
of the lowest quality liver grafts (DRI >1.8) despite an increase in
the risk of retransplantation with increasing DRI [1]. In Europe,
there was a steady rise in the median age (a key determinant
of poor donor quality) of deceased liver donors from 40 to
50 years old during the same period [7]. Most patients with early12 vol. 56 j 1404–1411
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Fig. 1. Comparison of liver graft survival rates after primary and retrans-
plantation at 1, 3, 5 years in the US for transplants performed from 1997 to
2004, based on OPTN data as of September 2, 2011. (http://optn.trans-
plant.hrsa.gov/latestData/rptStrat.asp [accessed 10.09.11].
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Fig. 3. Comparison of waitlist mortality among candidates for ﬁrst and repeat
liver transplantation using (A) MELD, (B) creatinine, (C) bilirubin, and (D) INR.
(Used with permission [9].)
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Fig. 4. Mortality in 6 months following waitlist registration in primary and
retransplantation. (Used with permission [10].)
JOURNAL OF HEPATOLOGYgraft complications will require retransplantation to achieve long
term survival. In this context, the success of liver transplantation
has the potential to exacerbate the scarcity of liver grafts by
increasing demand from candidates seeking early and late
retransplantation. Because of this, individual transplant centers
can expect a greater demand for retransplantation which may
justify a proactive review of center-based resources and polices
for these patients.MELD, MELD allocation system, and retransplantation
The majority of deceased donor liver graft allocation systems use
an urgency-based priority system with MELD as the primary
measure of urgency. Allocation to retransplant candidates is gen-
erally under the same paradigm as to ﬁrst transplant candidates.
However, patients with very early liver graft failure from PNF or
HAT are generally granted additional priority. For example, in the
US, patients meeting objective criteria for PNF or HAT within
7 days of transplant are granted the most urgent status, Status
1, and those with HAT occurring from 8 to 14 days are routinely
granted an exceptional MELD score of 40 [8]. Other retransplant
candidates are prioritized by their laboratory MELD score [8]. InJournal of Hepatology 2012a study of the US population of candidates waiting for second
(n = 557) and ﬁrst (n = 8431) liver transplants, Edwards et al.
found that the MELD score had reduced accuracy in predicting
death while waiting for retransplant (c-statistic 0.79, 95% CI
0.75–0.85) as compared to ﬁrst transplant (c-statistic 0.85, 95%
CI 0.84–0.86) [9] (Fig. 3). When examining the impact of the indi-
vidual laboratory components of the MELD, INR had a stronger
correlation whereas creatinine and bilirubin each had a weaker
correlation with waitlist mortality in retransplant candidates
when compared to primary candidates [9] (Fig. 3). Given the
higher prevalence of intrinsic renal insufﬁciency and chronic cho-
lestasis in prior liver transplant recipients [10], this data suggest
that worsening coagulopathy is an ominous sign in patients wait-
ing for retransplantation and that the MELD score may underes-
timate the risk of waitlist mortality relative to primary transplant
candidates.
So are patients waiting for retransplantation disadvantaged
under a MELD-based allocation system? A recent study from
Kim et al. concluded that implementation of MELD-based alloca-
tion in the US did not adversely affect access to transplantation
for retransplant candidates [10]. This study of 2081 retransplantvol. 56 j 1404–1411 1405
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Fig. 6. Relation between listing and MELD score and waiting list mortality in
primary transplant and retransplant candidates. Bars and whiskers represent
median, 25–75 percentiles and 2–98 percentile of MELD score at listing. Primary:
black, Retransplantation: red. (Used with permission [10].)
Table 1. Working deﬁnitions of ethical principles.
Ethical principle
Autonomy The right of the patient to accept or refuse 
any treatment relates to the patients being 
able to make informed decisions on their 
own behalf, rather than being subjected 
to paternalistic decisions being made for 
them by health care providers
Non-malfeasance Doing no harm or, even more 
appropriately, no further harm
Implies that the healthcare providers must 
and risks
Justice Implies the concern and duty to 
distribute limited health resources equally 
within a society and the decision of who 
gets what treatment 
(fairness and equality)
Utility
a, generally scarce, resource
Dignity and honesty The right of patients to be treated with
dignity and to receive information honestly
without suppression of important facts from
their healthcare providers
Working definition
Beneficence
provide benefits in the best interest of the
individual patient while balancing benefit
Maximizing the net benefit to society from
Frontiers in Liver Transplantationand 45,943 primary transplant candidates, before and after
implementation of MELD allocation in the US, found that despite
higher waitlist mortality rates in retransplant candidates when
compared to primary transplant candidates (1) the relative prob-
ability of a retransplant candidate surviving to receive a liver
graft increased more under MELD allocation than for those wait-
ing for a ﬁrst liver transplant and (2) rates of waitlist death for
both retransplant and primary transplant candidates were largely
unaffected by MELD allocation (Figs. 4 and 5). Importantly, in a
plot of waitlist mortality vs. MELD score at the time of listing,
retransplant candidates with a low MELD score (<25) had a
greater mortality than primary candidates yet, at higher MELD
scores (25–40), the waitlist mortality was lower for retransplant
candidates (Fig. 6). This latter analysis highlights the inﬂuence of
bias introduced by candidate selection process. Further evidence
of this selection bias is demonstrated in both Edwards et al. and
Kim et al. studies by comparing the demographics and MELD
scores at listing for retransplant and primary transplant candi-
dates. Retransplant candidates were younger and had higher
MELD scores at listing than primary transplant candidates
[9,10]. From these studies, one can conclude that even
though the MELD score underestimates waitlist of mortality
in retransplant candidates, that with implementation of the
MELD allocation system retransplant candidates had a greater1406 Journal of Hepatology 2012relative increase in access to liver grafts compared to primary
transplant candidates yet remained at a greater absolute risk
of waitlist mortality, particularly when the MELD score is
low. Furthermore, the candidate selection process has a power-
ful and important inﬂuence on access to retransplantation that
is difﬁcult to quantify in such retrospective studies of the allo-
cation system alone.
Several factors outside of the liver allocation system can inﬂu-
ence which liver transplant recipients with liver graft failure will
ultimately undergo retransplantation. These include several fac-
tors related to the individual patient, physician judgment, trans-
plant center policies, and experience as well as geographic donor
organ availability. Once graft failure is recognized, the patient’s
desire for and ability to endure retransplantation are assessed.
If the patient seeks retransplantation and the clinical care team
endorses it, the next step typically is a formal medical, surgical,
and psychosocial evaluation. If the patient is deemed an appro-
priate candidate and is registered on the waiting list for retrans-
plantation, appeals for MELD exceptions can be considered based
on special circumstances. Whether such an appeal is submitted
and accepted can be inﬂuenced by the patient’s degree of advo-
cacy, the physician’s medical judgment, the merits of the appeal,
and the reviewer’s interpretation of that appeal. Retransplant
candidates are generally sicker and seek a more technically
demanding procedure than primary candidates. These factors
can have a varied inﬂuence on the surgical team’s likelihood of
accepting an available liver graft that is based on their experience
and their perceived probability of another potentially more
appropriate liver graft offer [11,12]. Geographic variations in
organ availability and practice patterns can play a large role in
graft acceptance [13]. Lastly, while patients wait for an appropri-
ate liver graft, repeated assessments of the patient’s medical sta-
tus and continued desire for the procedure inform bedside
clinical decisions. This complex process is highly reliant on soundvol. 56 j 1404–1411
JOURNAL OF HEPATOLOGY
and ethical medical judgment and realistic patient expectations
within the context of severe liver graft scarcity.Application of medical ethics to retransplantation
Rational application of the fundamental principles of medical eth-
ics can assist the transplant community in liver graft allocation
policy development and bedside decision-making (Table 1). As
stewards of a scarce public resource, the transplant community
must balance the care for the individual patient with our obliga-
tions to society at large. Fulﬁllment of this duty requires reconcil-
ing these potentially conﬂicting roles. Although liver graft
allocation policies should strive to be objective and fair for all those
in need, the complex process outlined above entails several factors
that are difﬁcult or impossible to address objectively. To preserve
the public’s and our patient’s trust, polices should be as transpar-
ent and open as practically possible. The availability of donor
organs for transplantation is highly dependent on the public’swill-
ingness to donate organs. Loss of public trust, risks lower organ
donation rates and reduced access to transplant for our patients.
Society at large is therefore an important stakeholder, yet it is
our patientswhose lives hang in the balance. Asmost patientswith
liver graft failure would have some potential beneﬁt from retrans-
plantation, how can the clinical transplant teamdecline a patient’s
request for the procedure? When and how can we say no?
Such decision-making unfortunately is never simple or easy.
Precedence exists in other historical examples of scarce resources
such as the advent of insulin in 1922, penicillin in 1942, hemod-
ialysis in early 1960s and antiretroviral HIV medications in the
1980s [14,15]. Lessons from these experiences have informed
medical ethicists and clinicians of the pitfalls and challenges
when distributing scarce life saving medical treatments. Such
decisions can be inherently value laden and beneﬁt from efforts
to avoid prejudicial bias introduced by subjective assessments
of social worth. Medical criteria are not completely value-free
but often can inform decision-making once a paradigm is chosen,
i.e. whether to give priority to the most urgent cases, to those
with the best chance of survival or to those with the best chances
of quality of life afterwards. Although most liver transplant allo-
cation systems are currently based on the degree of urgency, pre-
dicted outcome after the procedure often plays both explicit and
implicit roles. For example, in the US, patients with hepatocellu-
lar carcinoma are granted additional priority while their tumor
stage is within the Milan Criteria and the predicted risk of tumor
recurrence after transplant remains reasonably low [8]. However,
if the tumor burden progresses beyond the Milan Criteria, the
additional priority for transplant is removed. Even though the
individual patient with excess tumor burden has the potential
of a longer life with a transplant as opposed to that without a
transplant, objective policy is in place to redirect liver grafts to
other patients. Placed in the context of medical ethics principles,
distributive justice (duty to distribute limited health resources
equally within a society), utility (duty to maximize the net ben-
eﬁt to society) and non-malfeasance (doing no harm) guide this
policy with patient autonomy (right of the patient to accept or
refuse a treatment), and beneﬁcence (best interest of the individ-
ual patient) taking a secondary role (Table 1). This paradigm may
serve as guideline for considering decision-making in candidate
selection and allocation policy for retransplantation.Journal of Hepatology 2012Key Points
• In the context of scarcity of available liver grafts, 
rationing provides a more useful construct than futility 
when approaching decision-making in candidate 
selection and organ allocation for retransplantation
• Assessments of public preferences, ethicist’s 
analysis and consensus conferences in the transplant 
professional community suggest support for outcome- 
based candidate and organ allocation decisions in liver 
retransplantation
• Although it is clear that a consensus on a minimum 
threshold for graft survival after retransplantation is 
 to achieve, a starting point for this discussion 
would be to develop guidelines to avoid listing 
retransplant candidates with a 5-year graft survival below 
50% and to de-list or inactivate retransplant candidates 
when the expected 1-year survival falls below 50%
difficult
When considering candidate selection in retransplantation,
there are two seminal decision nodes (1) the decision to place
the patient on the waiting list and (2) the decision to proceed
with retransplantation when a liver graft becomes available. In
retransplant candidate selection decisions, rational approaches
can be elucidated through the systematic application of ethical
principles. The autonomy of individual patients to accept or
refuse retransplantation should preclude proceeding with the
procedure if the patient does not desire it. However, ethicists
addressing similar issues in the context of autonomy and end-
of-life care, have highlighted the limits of individual autonomy
stating that refusing to let people do things to you is one thing
but demanding that people do things for you is another, particu-
larly if doing so may be at the expense of others [16]. In this light,
a patient with graft failure rightfully can refuse retransplantation
yet the principle of autonomy would not support the patient’s
demand to undergo the procedure. The principle of non-malfea-
sance provides little guidance in candidate selection decision-
making unless there is no feasible chance of survival with
retransplantation. It does, however, serve as an important remin-
der that retransplantation has greater morbidity and mortality
than primary transplant. A physician’s duty to beneﬁcence
obliges one to balance the risks and the beneﬁts of retransplanta-
tion in the individual patient with liver graft failure. This assess-
ment is dynamic and dependent on the clinical status of the
patient over time and highly reliant on the professional judgment
of physician. Dignity and honesty are imperative to avoid degra-
dation of patient–physician trust.
This process begins with a commitment to avoid placing
patients on the waiting list that the clinical team knows that they
would not proceed with retransplantation. Additionally, it
requires a frank discussion with listed patients that over time
they may become too sick for the procedure. When making deci-
sions to list a candidate or to proceed when a graft is available,
the risks of retransplantation may exceed the beneﬁts in the clin-
ical team’s judgment. In this case, there are reasonable grounds to
not proceed with the procedure. The more common and more
controversial scenario is that there is a potential net beneﬁt to
the individual patient but that expected beneﬁt is signiﬁcantlyvol. 56 j 1404–1411 1407
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less than that of another patient. Here, decision-makers can rely
on the principles of distributive justice and utility.
There at least two aspects of distributive justice and utility
that may apply to decision-making in retransplantation [17,18].
Firstly, one may consider that retransplant candidates may be
more or less deserving than primary transplant candidates. Apart
from acute liver graft failure, the arguments that retransplant
candidates are more deserving than primary candidates are
unconvincing when closely scrutinized. The arguments for higher
priority for the retransplant candidate suggest that there is an
obligation of the system to make up for suffering endured by
the patient due to a failed ﬁrst transplant or that the transplant
teams have a duty not to abandon their patients [17,19]. In the
setting of acute liver graft failure, currently polices described
above, generally allow for additional priority within the pool of
all liver transplant candidates. However, Ubel et al. have argued
that on the basis of having received a prior transplant, retrans-
plant candidates are neither more nor less deserving than pri-
mary transplant candidates. They contend that retransplant
candidates with iatrogenic causes of liver graft failure (i.e. PNF,
HAT) are not more deserving than ﬁrst liver transplant candidates
with native liver failure from natural causes. Additionally, they
argue that retransplant candidates are not less deserving of a sec-
ond liver graft, while others are waiting for a ﬁrst transplant,
because the retransplant candidate may have previously been
denied equal access to other public resources such as primary
health care, education or income. Whether or not this broad
interpretation of balancing non-health care injustices with addi-
tional heath care resources holds is arguable.
The second and more convincing argument is based on utility.
Ubel et al. argue that a utilitarian interpretation of distributive
justice (the greatest utility to society) justiﬁes lower priority to
the transplant candidate who has a lower predicted graft survival
[17]. They cite the generally lower graft survival rates in retrans-
plant recipients as grounds for reduced priority for retransplant
candidates. This recommendation would support the incorpora-
tion of survival models into liver graft allocation for patients
seeking retransplantation in a manner similar to that for patients
with hepatocellular carcinoma. That is, while the predicted post-
transplant survival after retransplantation is estimated to be sim-
ilar to primary transplant candidates, retransplant candidates
would have at least equal urgency-based priority to a liver graft.
Yet at some point, when the predicted survival reaches a mini-
mum threshold, the goal of the allocation system would no
longer be to promote equivalent priority among retransplant
and primary transplant candidates but would rather be to grant
a relative advantage to primary transplant candidates. The
mechanics of such a change in allocation may be complex yet evi-
dence-based approaches with serial re-evaluations, similar to
what has been done with HCC priority modiﬁcations in the US,
would serve as a path forward [20].
Absent formal policy measures guiding decision-making in
allocation of liver grafts to retransplant candidates, the decision
of whether or not to proceed with the use of a liver graft for
retransplantation relies heavily on the professional judgment of
the bedside clinicians. No change in allocation can or should
replace this clinical judgment yet the emotional involvement of
the clinical team can make difﬁcult decisions about the appropri-
ate use of liver grafts even harder. The transplant clinician’s role
as steward of a scarce public resource is best not enacted at the
bedside but unfortunately it often must. When this occurs, the1408 Journal of Hepatology 2012risk–beneﬁt discussions with the patient and family can take
two paths. The hard road entails a frank and decisively more dif-
ﬁcult explanation that despite some potential beneﬁt to the
patient, the liver graft will go to another patient with a greater
expected beneﬁt. The easier road is a conversation about the
patient’s individual risks and beneﬁts, which cites to some
degree, the futility of proceeding with retransplantation. How-
ever, in the vast majority of candidates, retransplantation is not
futile and care decisions made on this basis can obscure an hon-
est and frank discussion with the patient.Futility and retransplantation
The concept of medical futility, though often cited as the ratio-
nale for withholding an intervention, may obscure or limit the
application of more appropriate ethical principles in decision-
making regarding retransplantation. Notably, a practical working
deﬁnition for futility remains quite controversial [16,21,22]. The
components of futility that are generally agreed upon include
the inability to achieve a speciﬁc interventional related goal
and the probability of achieving that goal [23]. In liver transplan-
tation, the intervention related goal most often is long-term liver
graft and patient survival. Additional goals, such as avoiding
undue harm to the recipient and returning to an improved qual-
ity of life are no less important, though are value laden, and
therefore more vexing to apply in this context. The dominant
challenge in the application of futility in liver transplantation is
one of perspective. From the patient’s perspective, any potential
beneﬁt might exclude futility. From the ethicist’s perspective,
lack of success of 100 similar cases has been suggested as a work-
ing threshold to deﬁne futility [21,22]. From a societal perspec-
tive, given the current liver graft scarcity, it is unlikely that
survival rates as low as 1% would be considered satisfactory.
The transplant community has struggled to deﬁne an appropriate
minimum threshold for graft and patient survival after retrans-
plantation. Although several minimum thresholds have been con-
sidered, none have suggested graft survival rates less than 50% at
1 year [24–26]. Given the discrepant perspectives of what deﬁnes
retransplant success, futility is an impractical and potentially
divisive principle to apply in bedside decision-making and care
discussions with patients.Futility vs. rationing
Although there is some overlap in the concepts of futility and
rationing, the distinctions between them are illustrative in how
they may be applied to decision-making in retransplantation
(Table 2). The juxtaposition of these overlapping concepts has
been articulated by Jecker and Schneiderman [27]. When ration-
ing criteria refer to medical beneﬁt, the meaning of futility and
rationing share common features. For example, when access to
an intervention is based on medical beneﬁt and that estimated
beneﬁt is very low, both futility and rationing might be impli-
cated to withhold that intervention. Futility is generally applied
to decisions regarding individual patients yet rationing can be
applied to the general population, subgroups or individuals.
Rationing is deﬁned by the principle of maximizing distributive
justice within a population based on the degree of scarcityvol. 56 j 1404–1411
Table 2. Comparison of the characteristics of futility and rationing.
Characteristic Futility Rationing
Generally applied to Individual Individual or a population
Based on Threshold for unacceptable likelihood of success Distributive justice and fair allocation of resources
Empirical evidence Degree of scarcity 
Requires scarce resource No Yes
Could reasonably be based on cost No Yes
Yes Yes
Requires assessment of therapeutic Yes No
Defined by
benefit
Often refers to therapeutic benefit
JOURNAL OF HEPATOLOGYwhereas futility is deﬁned by the available empirical evidence
that predicts the likelihood of not achieving a desired outcome.
Lastly, rationing implies an inﬂuence of resource scarcity whereas
futility does not. That is, under conditions of scarcity, even bene-
ﬁcial interventions may be denied based on rationing.Rationing and retransplantation
When considering candidate selection and allocation decisions in
retransplantation, rationing provides a more practical and forth-
right construct than futility. Unlike other medical rationing, the
indisputable gap between the supply and demand for scarce
donor organs, makes rationing in transplant decision-making an
inevitable reality. Although cost and capacity for higher volume
within transplant centers could also create a need to ration access
to liver transplantation, the lack of sufﬁcient organs to satisfy the
demand establishes the need for rationing as a fact rather than a
hypothetical case. Using organ scarcity as the foundation of deci-
sion-making lays the framework for stakeholder expectations.
Deﬁning minimum thresholds for success remains integral to
decision-making but the discrepant perspectives of how success
is deﬁned is much less troublesome within the construct of
rationing than that of futility. When rationing is the expectation
of all the stakeholders, including the patient, the goal of retrans-
plantation is not merely to achieve any possible beneﬁt for an
individual patient regardless of how small. Rather, the goal is to
exceed a predetermined minimum expected graft survival. In
doing this, bedside decision-making and conversations with
patients and their families are no less difﬁcult but are likely to
be more forthright and honest.
Allocation polices based on incorporating outcome measures
for retransplant patients would be consistent with the principle
of utility and the utilitarian application of distributive justice. If
created in a fair and transparent manner, such polices have the
potential to minimize discrepant expectations of patients and
the transplant team during bedside decision-making. Patients
with a poor expected outcome would not be placed on the wait-
ing list for retransplantation. Patients already on the waitlist who
had clinical deterioration and resultant poor expected outcome
with retransplantation would either be reduced in priority, be
made temporally inactive or be removed from the waiting list.
There are at least two major challenges when applying
rationing and outcomemeasures in retransplantmedical decision-
making: (1) determining what is the minimum threshold for
acceptable graft survival and (2) identifyingwho should determine
that threshold. The transplant community must work with theJournal of Hepatology 2012public to identify what is an appropriate minimum threshold for
graft survival after retransplantation. Surveys of the general public
indicate support an approach that balances utilitarianism with
other principles including equal opportunity and personal respon-
sibility yet none quantiﬁed a minimum graft survival. In a survey
study, Ratcliff et al. quantiﬁed the tradeoffs of utilitarianism and
other principles using a conjoint analysis. In their survey con-
ducted in the United Kingdom (UK), 303 university employees
were asked to allocate organs among two groups that varied based
on several potential patient characteristics. Among the character-
istics tested, expected survival after transplant was the strongest
relative attribute (32%), then alcoholic etiology of liver disease
(30%), age (24%), time on waiting list (6%), and prior transplanta-
tion (6%) [28]. In another survey of 138 members representing
the general public in Pittsburgh Pennsylvania, Ubel et al. found that
poor survival after liver transplant was associated with a prefer-
ence for a lower priority for transplant, an effect that was stronger
if the candidate was seeking retransplantation [18]. Another sur-
vey study in the UK that included 1000 members of the general
public found that candidate’s age and outcomewere the twomost
important factors when allocating liver grafts [29].
The liver transplant community has been working to deﬁne a
minimum acceptable threshold for graft survival at national con-
sensus conferences. A national colloquium in the United Kingdom
in 1998 concluded that in that country a patient should be
offered liver transplantation only if there is an expected 5-year
survival that is greater than 50% [24]. These criteria were recom-
mended for decisions regarding placing patients on the waiting
list as well as for removing them from the waiting list. Addition-
ally, they recommended that allocation should aim at maximiz-
ing outcome in preference to allowing every potential recipient
an equal chance to receive an organ. With regard to retransplan-
tation, this group suggested that their 50% 5-year survival guide-
line should be relaxed for early retransplant candidates i.e. those
with PNF, but should hold ﬁrm for late retransplantation [24]. In
2008, the UK Liver Advisory Group concurred with the previous
UK recommendation of a 5-year 50% survival threshold yet cau-
tioned against formal de-listing criteria until evidence-based
guidelines could be developed [25]. A US-based consensus con-
ference in December 2003 also addressed this topic [26].
Although a minimum graft survival threshold of approximately
50% was suggested, the time point after transplantation was left
undeﬁned but 1- and 5-year time points were considered [26].
For allocation, the MELD and urgency-based system was lauded
yet in the case of retransplantation, a modiﬁed system that incor-
porated both pre- and post-transplant survival was considered.
The allocation schema for patients with large hepatocellularvol. 56 j 1404–1411 1409
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carcinomas was identiﬁed as a potential road map for developing
de-listing criteria. As discussed above, that schema provides prior-
ity to hepatocellular cancer withinMilan Criteria but removed the
additional priority if the tumor exceeds Milan Criteria. The group
acknowledged that since transplant candidates with poor esti-
mated post-transplant survival represent those with the highest
mortality without transplant, any criteria to deﬁne a minimum
acceptable survival threshold should be strongly evidence-based
and biased in favor of proceeding with transplantation [26].
Importantly, all of these conferences raised concerns about the
application of models with limited accuracy in predicting post-
transplant survival [24–26]. Although it is clear that a consensus
on aminimumsurvival threshold is difﬁcult to achieve, it is imper-
ative to work toward that goal. A starting point for this discussion
would be to develop guidelines to avoid listing retransplant candi-
dates with a 5-year graft survival below 50% and to de-list or inac-
tivate retransplant candidates when the expected 1-year survival
falls below 50%.Prognostic models in retransplantation
Several mathematical models have been developed to predict
survival after retransplantation using multivariate regression
methods and were previously and recently summarized [30,31].
Among the different predictive factors examined, preoperative
serum total bilirubin and serum creatinine have consistently pro-
vided the most signiﬁcant prognostic power. Other important
factors identiﬁed include HCV status, recipient age, donor age,
warm and cold ischemia times, UNOS status (ICU, hospital ward,
ambulatory), mechanical ventilator support, and interval to
retransplantation. Post-retransplantation survival rates are
higher with younger recipients, longer intervals between trans-
plants (>2 months), and retransplantation before severe decom-
pensation. Whereas patients with emergent/urgent early
(<1 week up to 2 months) retransplantation, graft primary non-
function, physical debility, MELD score >25, creatinine >2 mg/dl,
total bilirubin >13 mg/dl, Child-Turcotte-Pugh score P10, donor
age >60 years, donation after cardiac death, cold ischemic time
>12 h, warm ischemic time >75 min, fared worse. Such prognos-
tic models can be used to risk stratify candidates for repeat liver
transplantation with, at best, moderate accuracy, c-statistic about
0.65 for 1-year survival [32]. The most signiﬁcant challenges to
further improvement in the accuracy of these models include
the inability to model random operative and perioperative events
that are by deﬁnition unpredictable. Additionally, as the vast
majority of these models were developed on patients that already
had undergone retransplantation, not in patients being consid-
ered for the procedure, a selection bias may limit the generaliz-
ability to clinical decision-making when selecting candidates to
place on the waiting list. Improved evidence-based models devel-
oped in liver recipients not yet listed for retransplant are needed.
Prospective registries of prior transplant candidates being consid-
ered for re-listing may aid this goal. This is particularly true with
elective retransplantation for chronic graft failure or in geo-
graphic areas of extreme organ shortage, where the clinical status
of the candidate can change during a prolonged waiting period.
However, once a candidate is on the waiting list for retransplan-
tation, the prognostic models can be used to inform the decision
of whether or not to proceed with retransplantation when a liver
graft becomes available. Models that account for both patient and1410 Journal of Hepatology 2012donor characteristics, such donor age and donation after cardiac
death, are more complex but may provide a more accurate esti-
mate of the probability of graft and patient survival after retrans-
plantation. Such models already exist, yet their complexity has
limited their general acceptance [33].Conclusions
The concept of medical futility, though often cited as the ratio-
nale for withholding an intervention, may obscure or limit the
application of more appropriate ethical principles in decision-
making in retransplantation. When considering candidate selec-
tion and allocation decisions in retransplantation, rationing pro-
vides a more practical and forthright construct than futility.
Using organ scarcity as the origin of decision-making lays frame-
work for stakeholder expectations. Deﬁning the minimum
thresholds for success remains integral to such decision-making
but discrepant perspectives of how success is deﬁned are much
less troublesome within the construct of rationing than within
the construct of futility. When rationing is the expectation of
all the stakeholders, including the patient, the goal of retrans-
plantation is not merely to achieve any possible beneﬁt for an
individual patient but rather the goal is to exceed a predeter-
mined minimum expected graft survival. Although it is clear that
a consensus minimum threshold for graft survival is difﬁcult to
achieve, it is imperative to work toward that goal. A starting point
for this discussion would be to develop guidelines to avoid listing
retransplant candidates with an expected 5-year graft survival
below 50% and to de-list or inactivate retransplant candidates
when the expected 1-year survival falls below 50%. An evi-
dence-based utilitarian approach with serial re-evaluations, sim-
ilar to what was done with HCC priority modiﬁcations in the US,
may serve as a path forward.Conﬂict of interest
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